Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Congestive Heart Failure (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. There are two types of heart failure including systolic heart failure (left ventricle loses its ability to contract normally) and diastolic heart failure (left ventricle loses its ability to relax normally). The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 13, 44, 38, 1, 7, 91, 27 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 20 and 5 molecules, respectively.

Congestive Heart Failure (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Congestive Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Congestive Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Cardiovascular)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

4TEEN4 Pharmaceuticals GmbH
Adicet Bio Inc
Adrenomed AG
AgeX Therapeutics Inc
Akebia Therapeutics Inc
Allysta Pharmaceuticals Inc
AnaCardio AB
Anchored Rsk3 Inhibitors LLC
Angion Biomedica Corp
Animatus Biosciences LLC
Antlia Bioscience Inc
APIE Therapeutics Inc
Araim Pharmaceuticals Inc
ARCA biopharma Inc
ARMGO Pharma Inc
Ascendia Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Athersys Inc
Avery Therapeutics Inc
Bayer AG
Betagenon AB
BioCardia Inc
Biopeutics Co Ltd
BlueRock Therapeutics LLC
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
C&C BioPharma LLC
Capricor Therapeutics Inc
Cardiac RSK3 Inhibitors LLC
Cardiol Therapeutics Inc
Cardior Pharmaceuticals GmbH
CCRP Therapeutics GmbH
Celixir Ltd
Cell Tech Pharmed Co
Cellvation Inc
Chong Kun Dang Holdings Corp
Chong Kun Dang Pharmaceutical Corp
Corteria Pharmaceuticals SAS
Creative Medical Technology Holdings Inc
CuronBiotech Inc
Cytokinetics Inc
Daiichi Sankyo Co Ltd
DiNAQOR AG
Dynomics Inc
Eli Lilly and Co
Elyson Pharmaceutical Co Ltd
Ethicare GmbH
Evotec SE
Exscien Corp
F. Hoffmann-La Roche Ltd
G3 Pharmaceuticals Inc
GB Sciences Inc
Genome Biologics UG
GlaxoSmithKline Plc
Guangdong East Sunshine Pharmaceutical Co Ltd
Heartseed Inc
Help Therapeutics
Hemostemix Inc
Hunan Jingfeng Pharmaceutical Co Ltd
Huons Co Ltd
Hyloris Pharmaceuticals SA
I-Cordis LLC
iHeart Japan Corp
Imara Inc
Imbria Pharmaceuticals Inc
Immunwork Inc
Innolife Co Ltd
Innopharmax Inc
Inserm Transfert SA
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Johnson & Johnson
Katakura Industries Co Ltd
KBP Biosciences Co Ltd
Larix Bioscience LLC
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lexicon Pharmaceuticals Inc
Madeleine Pharmaceuticals Inc
Mesoblast Ltd
Metcela Inc
Mitsubishi Tanabe Pharma Corp
Moderna Inc
NanoCor Therapeutics Inc
NeoProgen Inc
Novartis AG
Novelstar Pharmaceuticals Inc
NovoMedix LLC
Olatec Therapeutics LLC
Organicell Regenerative Medicine Inc
Orig3N Inc
Orion Corp
Orizuru Therapeutics Inc
Otsuka Pharmaceutical Co Ltd
Palatin Technologies Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharchoice Therapeutics Inc
PhaseBio Pharmaceuticals Inc
Phrixus Pharmaceuticals Inc
Poxel SA
Procella Therapeutics AB
Prolifagen LLC
Proveca Ltd
Q BioMed Inc
Qanatpharma GmbH
Quantum Genomics SA
Qurgen Inc
Ramino-Bio Ltd
Recardio Inc
Regeneron Pharmaceuticals Inc
Renova Therapeutics Inc
Ribomic Inc
Rivus Pharmaceuticals Inc
Rnatives Ltd
Rockwell Medical Inc
Saillant Therapeutics BV
Saje Pharma LLC
Saliogen Therapeutics Inc
Salubris Biotherapeutics Inc
Sana Biotechnology Inc
Sanofi
Sarfez Pharmaceuticals Inc
scPharmaceuticals Inc
Senju Pharmaceutical Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Hongyitang Biomedical Technology Co Ltd
Shanghai Life Science & Technology
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong Pharm Co Ltd
Signal Pharma Ltd
Silver Creek Pharmaceuticals Inc
siRNAgen Therapeutics Corp
Sorrento Therapeutics Inc
Stemedica Cell Technologies Inc
Sumocor LLC
Sun Pharma Advanced Research Company Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
T&R Biofab Co Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
Tenaya Therapeutics Inc
Titan Pharmaceuticals Inc
Toa Eiyo Ltd
Torrent Pharmaceuticals Ltd
TransThera Sciences (Nanjing) Inc
TreeFrog Therapeutics SAS
Trio Medicines Ltd
Triple-Gene LLC
U.S. Stem Cell Inc
Valo Health LLC
Viatris Inc
ViCardia Therapeutics Inc
Viera BioScience Inc
Vifor Pharma Ltd
Viridian Therapeutics Inc
Viscofan BioEngineering
Windtree Therapeutics Inc
Wuhan LL Science and Technology Development Co Ltd
XyloCor Therapeutics Inc
YAP Therapeutics Inc
Zensun (Shanghai) Sci & Tech Co Ltd